Clinical trial
A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistаnt Acute Leukemia.
NCT04000698 is registered in ClinicalTrials.gov with Federal Research Institute of Pediatric Hematology, Oncology and Immunology as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRαβ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistаnt Acute Leukemia.
- Lead sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
- Phase
- Phase 3
- Overall status
- Unknown status
- Start date
- October 15, 2019
- Completion date
- December 31, 2022
- Enrollment
- 25 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
refractory acute lymphoblastic leukemia, refractory acute myeloid leukemia